3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
CNS
1
Conditions
Carcinoma, Renal Cell
19
Kidney Neoplasms
8
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
von Hippel-Lindau Disease
4
Neoplasm Metastasis
2
Recurrence
1
Pheochromocytoma
1
Paraganglioma
1
Neoplasms
1
Metastatic Castration-Resistant Prostate Cancer
1
Glioblastoma
1
Carcinoma
1
Breast Neoplasms
1
Adenoma, Islet Cell
1
Interventions
Sunitinib
4
Everolimus
4
Endoscopic Ultrasound-Guided Fine Needle Aspiration
2
napabucasin
1
lanreotide
1
irinotecan sucrosofate
1
belzutifan
1
Taxes
1
Paclitaxel
1
Oxaliplatin
1
Octreotide
1
Leucovorin
1
LY2940680
1
Irinotecan
1
Gemcitabine
1
Fluorouracil
1
Albumin-Bound Paclitaxel
1
90Y-octreotide, DOTA-Tyr(3)-
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Adenoma, Islet Cell
×
belzutifan
×
Clear all
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA